Spero Therapeutics Q3 net loss widens on SP001 licensing payment
Spero Therapeutics Q3 net loss widens on SP001 licensing payment Overview US biopharma firm's Q3 rev
Spero Therapeutics Q3 net loss widens on SP001 licensing payment Overview US biopharma firm's Q3 rev